Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

papaverine (Rx)Brand and Other Names:ParaTime SR

 
 
 

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

capsule, extended release

  • 150mg

injectable solution

  • 30mg/mL
more...

Arterial Spasm

Sustained release oral formulation: 150 mg PO q8-12hr OR 300 mg PO q12hr

Injection solution: 30-65 mg (up to 120 mg if needed) IV/IM; may repeat q3hr

Cardiac extrasystoles: Administer 2 doses 10 minutes apart

Admin IV by slow push (1-2 minutes)

Other Indications & Uses

Relief of cerebral & peripheral ischemia associated with arterial spasm, & MI complicated by arrhythmias

Increase collateral circulation in treatment of acute vascular occlusion

Historical uses (no longer recommended as first-line treatment): Angina, vascular encephalopathy, cerebral angiospasm, chronic peripheral vascular disease, GI spasm, dysmenorrhea, biliary colic, bronchial asthma

Off-label: Erectile dysfunction (intracavernosal inj)

Dosage Forms & Strengths

capsule, extended release

  • 150mg

injectable solution

  • 30mg/mL
more...

Arterial Spasm

6 mg/kg/day IV/IM divided q6hr

Administer IV by slow push (1-2 minutes)

Arterial Spasm

Sustained release oral formulation: 150 mg PO q8-12hr OR 300 mg PO q12hr

Injection solution: 30-65 mg (up to 120 mg if needed) IV/IM; may repeat q3hr

Cardiac extrasystoles: Administer 2 doses 10 minutes apart

Admin IV by slow push (1-2 minutes)

Next

Interactions

Interaction Checker

papaverine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency not defined

            BP changes

            Flushing

            Tachycardia

            Depression

            Dizziness

            HA

            Drowsiness

            Malaise

            Raised intracranial pressure

            Pruritus

            Rash

            Anorexia

            Diarrhea

            Dry mouth

            Constipation

            Nausea

            Vomiting

            Hepatitis (rare)

            Cirrhosis (rare)

            Priapism (with intracavernosal inj)

            Sweating

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity

            Complete AV block

            Cautions

            Rapid inj may cause fatal apnea

            Glaucoma, cardiac conduction disorder

            Intracavernosal inj may lead to priapism

            Chronic use may lead to dependence due to CNS depressant effect

            Discontinue if signs or symptoms of hepatic hypersensitivity

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: unknown; use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Synthetic derivative of opium

            Smooth muscle spasmolytic via inhibition of oxidative phosphorylation & interference with Ca++ during muscle contraction as well as increase in cAMP from inhibition of cyclic nucleotide phosphodiesterase; most pronounced effect on blood vessels, including coronary, cerebral, pulmonary, gastrointestinal sphincter relaxation & peripheral arteries

            Depresses cardiac muscle excitability

            Pharmacokinetics

            Onset: Rapid

            Duration: PO: 12 hr

            Protein Bound: 90%

            Half-life elimination: 0.5-1.5hr

            Metabolism: Liver, via glucuronidation

            Excretion: Urine

            Previous
            Next

            Administration

            IV Incompatibilities

            Solution: LR

            Additive: aminophylline with trimecaine

            Syringe: diatrizoate meglumine/diatrizoate sodium, ioxaglate meglumine/ioxaglate sodium

            IV Compatibilities

            Solution: dextrose solutions, fructose solutions, saline, dextrose-saline, Ringer's, Na-lactate 1/6M

            Additive: theophylline

            Syringe: iohexol, iopamidol, phentolamine

            IV/IM Administration

            IM or slow IV over 1-2 min

            Storage

            Store vial at room temp, do not freeze

            Protect from light

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.